1 2424

Cited 5779 times in

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

 Yung-Jue Bang  ;  Eric Van Cutsem  ;  Andrea Feyereislova  ;  Hyun C Chung  ;  Lin Shen  ;  Akira Sawaki  ;  Florian Lordick  ;  Atsushi Ohtsu  ;  Yasushi Omuro  ;  Taroh Satoh  ;  Giuseppe Aprile  ;  Evgeny Kulikov  ;  Julie Hill  ;  Michaela Lehle  ;  Josef Rüschoff  ;  Prof Yoon-Koo Kang 
 LANCET, Vol.376(9742) : 687-697, 2010 
Journal Title
Issue Date
Adenocarcinoma/drug therapy* ; Adenocarcinoma/metabolism ; Adenocarcinoma/mortality ; Aged ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/administration & dosage* ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Capecitabine ; Cisplatin/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Drug Therapy, Combination ; Esophagogastric Junction* ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/analogs & derivatives ; Humans ; Male ; Middle Aged ; Receptor, ErbB-2/biosynthesis ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/mortality ; Survival Analysis ; Trastuzumab ; Treatment Outcome
BACKGROUND: Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer.

METHODS: ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries. Patients with gastric or gastro-oesophageal junction cancer were eligible for inclusion if their tumours showed overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation. Participants were randomly assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in combination with intravenous trastuzumab. Allocation was by block randomisation stratified by Eastern Cooperative Oncology Group performance status, chemotherapy regimen, extent of disease, primary cancer site, and measurability of disease, implemented with a central interactive voice recognition system. The primary endpoint was overall survival in all randomised patients who received study medication at least once. This trial is registered with ClinicalTrials.gov, number NCT01041404.

FINDINGS: 594 patients were randomly assigned to study treatment (trastuzumab plus chemotherapy, n=298; chemotherapy alone, n=296), of whom 584 were included in the primary analysis (n=294; n=290). Median follow-up was 18.6 months (IQR 11-25) in the trastuzumab plus chemotherapy group and 17.1 months (9-25) in the chemotherapy alone group. Median overall survival was 13.8 months (95% CI 12-16) in those assigned to trastuzumab plus chemotherapy compared with 11.1 months (10-13) in those assigned to chemotherapy alone (hazard ratio 0.74; 95% CI 0.60-0.91; p=0.0046). The most common adverse events in both groups were nausea (trastuzumab plus chemotherapy, 197 [67%] vs chemotherapy alone, 184 [63%]), vomiting (147 [50%] vs 134 [46%]), and neutropenia (157 [53%] vs 165 [57%]). Rates of overall grade 3 or 4 adverse events (201 [68%] vs 198 [68%]) and cardiac adverse events (17 [6%] vs 18 [6%]) did not differ between groups.

INTERPRETATION: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.